Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Xbrane Signs Term Sheet for China Distribution of Cancer Drug

publication date: Nov 1, 2016
Xbrane Biopharma, a Swedish company, signed a non-binding term sheet with an unnamed China pharma for China distribution of Spherotide, a long-acting generic form of Decapeptyl®, a cancer drug. The unnamed China pharma will pay $1.9 million on signing and make three additional milestone payments to bring the total to $7.6 million. Xbrane describes the China pharma as a large company that is active in all sectors of China's pharma market. Xbrane will manufacture the drug, but the China company will be responsible for all clinical trials. Launch is expected in 2021. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital